Send to

Choose Destination
See comment in PubMed Commons below
Neurology. 2003 Nov 25;61(10):1438-40.

Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.

Author information

Department of Neurological Sciences, Rush University, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA.


The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center